Aditxt Strengthens Board with Women's Health Leader Saundra Pelletier

Aditxt (NASDAQ: ADTX) has made a strategic move by appointing Saundra Pelletier, CEO of Evofem Biosciences (OTCPK: EVFM), to its Board of Directors. This appointment is part of Aditxt's broader strategy to enhance its focus on women's health and accelerate the commercialization of its innovations. Pelletier's extensive experience in the pharmaceutical industry, particularly in women's reproductive health, is expected to be invaluable as Aditxt advances its mission. Her leadership at Evofem, marked by the successful launch of Phexxi(R) and the acquisition of SOLOSEC(R), underscores her capability to drive growth and innovation in the health sector.

Aditxt operates as an innovation platform aimed at accelerating health innovations through collaboration among research institutions, industry partners, and shareholders. The company is currently focusing on immune health and precision health, with plans to expand into public health and women's health. Strategic partnerships, including an arrangement with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF) and a merger agreement with Evofem, are central to Aditxt's strategy to address urgent health challenges. These developments highlight Aditxt's commitment to fostering innovation and making a significant impact in the health sector. For more details, visit the full press release.